To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

November 20, 2019___

Today's Rundown

Featured Story

Vertex, CRISPR’s gene-editing treatment for blood disorders shows promise in early data

CRISPR Therapeutics and Vertex Pharmaceuticals unveiled early data from the first company-backed study to test a CRISPR-based medicine in humans. The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment for patients who need chronic care, wrote Cantor Fitzgerald analysts in a note.

Top Stories

Bischofberger-helmed Kronos nabs Celgene research exec as new CMO

Fierce 15 winner Kronos Bio has poached Jorge DiMartino, M.D., Ph.D., as its chief medical officer and executive vice president of clinical development.

Werewolf Therapeutics uncloaks with $56M and shape-shifting cancer meds

It’s a full moon for Werewolf Therapeutics as the company comes out of stealth with $56 million and an approach it believes can cut through the toxic effects that have limited the use of certain cancer-killing agents. It is working on medicines that are delivered systemically but stay inactive within the body until they reach a tumor.

GHO raises €975M European healthcare fund

GHO Capital has raised €975 million ($1.1 billion) to invest in European healthcare companies. The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

Tissium raises €39M to advance tech with drug delivery uses

Tissium has raised €38.8 million ($42.9 million) to fund work on synthetic programmable polymers with applications in drug delivery and other areas. The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.

Sanofi to assimilate Aetion's real-world data platform into its own

Sanofi is launching a companywide project to incorporate its real-world data platform with Aetion’s analytics system to better develop studies capable of standing up to regulatory requirements.

Lilly putting $400M into U.S. diabetes production, adding 100 jobs

Eli Lilly faced critics of rising insulin prices this year by introducing a generic version of its popular Humalog priced at half the cost. Now the drugmaker is investing $400 million in its Indianapolis production site so it can make more diabetes treatments and prepare for pipeline products. 

Enrollment Showcase

A Credential for the Future of Health Care

Join the future of health care with the flexibility and convenience of an online program.

Resources

[Whitepaper] Modernizing clinical trials with Amazon Web Services (AWS)

From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks

[Whitepaper] Why Companies Leverage the Cloud to Smooth the Path to FDA Approval

See why visionaries outsource the design and management of the infrastructure allowing their scientists to innovate.

[Whitepaper] Medical Affairs 2025 Excellence in the Era of Precision Medicine

Medical Affairs 2025 brings together leading perspectives from AstraZeneca, Bristol-Myers Squibb, Merck, Lilly, and other innovative life sciences organizations on key challenges impacting medical affairs and a roadmap for success in the coming decade.

[Whitepaper] The State of Real-World Evidence in Biopharma

This whitepaper provides a snapshot of where the biopharma industry is now, where it's heading, and how companies are allocating their resources to adapt & grow.

[Whitepaper] IBM Clinical Development: Key solutions for more efficient clinical research

IBM’s highlighted solutions reside in a security-rich cloud environment—home for capturing, managing and analyzing clinical study data with control, accuracy and confidence. These solutions lay the groundwork for further integration with IBM® Watson® cognitive technology.

[Whitepaper] How Big is the US Market for Medical Devices and Technologies?

Inpatient View and Outpatient View are powered by robust data assets and use sophisticated projection methodologies to help ensure accuracy of reporting.

[Whitepaper] The importance of early key opinion leader outreach in the biologics and biosimilars marketplace

Acknowledging various stakeholder networks, as well as recognizing variances within the regulatory environment, we believe, is essential for companies looking to uncover the right decision-makers in support of biologics or biosimilars. Learn more.

[Whitepaper] 5 Best Practices for Marketing Medical Devices

Discover solutions to the most common challenges faced by medical device companies.

[Whitepaper] The Impact of Step-Therapy Policies on Patients

Download this complimentary paper that explores the practice of step therapy and its impact on key stakeholders in the US healthcare system.

[Whitepaper] Q2 2019 Biopharma licensing report

18 high-value new licensing deals worth in excess of $500 million took place during the second quarter of 2019 -Get the Q2 2019 Biopharma licensing report for full details and insights.

[Whitepaper] Synthesizing Success: Six Principles For Getting Pharmaceutical Development Right From The Start

Is your API development on track?

[Infographic] Implement the Patient Voice to Build an Effective Engagement App

Get the latest data on how people are using apps to manage their health, and learn how you can leverage it in the development of your next clinical trial app.

[eBook] Customer Experience: Shaping Digital Healthcare

Report: How to design digital services that deliver value and improve outcomes for patients, healthcare professionals and the healthcare systems they serve

[Whitepaper] How to succeed by failing faster

This white paper examines the skyrocketing cost of drug development and provides step-by-step guidance for executing a successful fail fast strategy.

[Whitepaper] Innovative Funding Models for Treatment of Cancer and Other High-Cost Chronic Noncommunicable Diseases

A global landscape study of funding trends and innovations.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events